Drug Information

Drug (ID: DG02014) and It's Reported Resistant Information

• Name: Selinexor
• Synonyms: Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F
• Indication:
  In total 1 Indication(s)
  Recurrent glioblastoma [ICD-11: 2A00]; Phase 2
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Multiple myeloma [ICD-11: 2A83]; [1]
• Target: Exportin-1 (XPO1); XPO1_HUMAN
• Formula: C17H11F6N7O
• IsoSMILES: C1=CN=C(C=N1)NNC(=O)/C=C\\N2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
• InChI: InChI=1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)/b4-1-
• InChIKey: DEVSOMFAQLZNKR-RJRFIUFISA-N
• PubChem CID: 71481097
• TTD Drug ID: D00LNW
• INTEDE ID: DR1472

Type(s) of Resistant Mechanism of This Drug

  MRAP: Metabolic Reprogramming via Altered Pathways

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Multiple myeloma [ICD-11: 2A83]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Metabolic Reprogramming via Altered Pathways (MRAP)

Key Molecule: Cytidine triphosphate synthase 1 (CTPS1) [1]

• Metabolic Type: Nucleic acid metabolism
• Resistant Disease: Multiple myeloma [ICD-11: 2A83.0]
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: NCI-H929 cells; Bone marrow; Homo sapiens (Human); CVCL_1600
• Experiment for Molecule Alteration: qRT-PCR; Western blot analysis
• Experiment for Drug Resistance: Cell viability assay
• Mechanism Description: Among these, upregulation of CTPS1 was associated with poor prognosis in MM and drug resistance recurrence. CTPS1 is mainly involved in cytidine metabolism and nucleic acids metabolism.

Key Molecule: Cytidine triphosphate synthase 1 (CTPS1) [1]

• Metabolic Type: Nucleic acid metabolism
• Resistant Disease: Multiple myeloma [ICD-11: 2A83.0]
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: MM1 S cells; Blood; Homo sapiens (Human); CVCL_8792
• Experiment for Molecule Alteration: qRT-PCR; Western blot analysis
• Experiment for Drug Resistance: Cell viability assay
• Mechanism Description: Among these, upregulation of CTPS1 was associated with poor prognosis in MM and drug resistance recurrence. CTPS2 is mainly involved in cytidine metabolism and nucleic acids metabolism.

Key Molecule: Cytidine triphosphate synthase 1 (CTPS1) [1]

• Metabolic Type: Nucleic acid metabolism
• Resistant Disease: Multiple myeloma [ICD-11: 2A83.0]
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: U266B1 cells; Blood; Homo sapiens (Human); CVCL_0566
• Experiment for Molecule Alteration: qRT-PCR; Western blot analysis
• Experiment for Drug Resistance: Cell viability assay
• Mechanism Description: Among these, upregulation of CTPS1 was associated with poor prognosis in MM and drug resistance recurrence. CTPS3 is mainly involved in cytidine metabolism and nucleic acids metabolism.

Key Molecule: Cytidine triphosphate synthase 1 (CTPS1) [1]

• Metabolic Type: Nucleic acid metabolism
• Resistant Disease: Multiple myeloma [ICD-11: 2A83.0]
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: RPMI 8226 cells; Peripheral blood; Homo sapiens (Human); CVCL_7353
• Experiment for Molecule Alteration: qRT-PCR; Western blot analysis
• Experiment for Drug Resistance: Cell viability assay
• Mechanism Description: Among these, upregulation of CTPS1 was associated with poor prognosis in MM and drug resistance recurrence. CTPS4 is mainly involved in cytidine metabolism and nucleic acids metabolism.

Key Molecule: Cytidine triphosphate synthase 1 (CTPS1) [1]

• Metabolic Type: Nucleic acid metabolism
• Resistant Disease: Multiple myeloma [ICD-11: 2A83.0]
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: 293 T cells; Blood; Homo sapiens (Human); N.A.
• Experiment for Molecule Alteration: qRT-PCR; Western blot analysis
• Experiment for Drug Resistance: Cell viability assay
• Mechanism Description: Among these, upregulation of CTPS1 was associated with poor prognosis in MM and drug resistance recurrence. CTPS5 is mainly involved in cytidine metabolism and nucleic acids metabolism.

References

• Ref 1: Cytidine triphosphate synthase 1-mediated metabolic reprogramming promotes proliferation and drug resistance in multiple myeloma. Heliyon. 2024 Jun 20;10(13):e33001.